CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2019—Hematogenix announced the availability of the assessment of B-cell maturation antigen by flow cytometry and immunohistochemistry at its facilities in China, Asia, Europe, and the United States.
“We have successfully validated multiple BCMA assays by both flow cytometry and immunohistochemistry in selected indications, including multiple myeloma. With the use of these two platforms to assess BCMA, we can consistently provide a broad menu of testing services to support cancer research,” Hytham Al-Masri, MD, CEO and founder of Hematogenix, said in a company statement.
Pages: 1 2